# Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia

> **NCT04418128** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Gyeongsang National University Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Corona Virus Infection
- COVID-19

## Interventions

- **DRUG:** Nafamostat Mesylate

## Key facts

- **NCT ID:** NCT04418128
- **Lead sponsor:** Gyeongsang National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-10
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418128, "Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04418128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*